https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0717-92272001000100010
Enfermedades Extrapiramidales

 

Rev Chil Neuro-Psiquiat 2001; 39(1): 6 

ARTÍCULO ESPECIAL

 

Enfermedades Extrapiramidales 

Extra-pyramidal Disorders 

 

Pedro Chaná

Universidad de Santiago de Chile, Hospital DIPRECA.



L

El genoma humano cuenta con alrededor de 85.000 genes, en 1990 habían sido identificados y mapeados 1.772. En 1996 el número de genes identificados llegaba al doble, sesenta y dos de ellos se habían relacionado a diferentes enfermedades humanas. El crecimiento ha sido explosivo con la llegada de la industria de la genética que ve en este campo una opción comercial para definir los mecanismos moleculares de las patologías y la posibilidad de desarrollar principios terapéuticos en forma eficiente y rápida (

Los trastornos del movimiento son un área especialmente beneficiada por estos adelantos. La enfermedad de Huntington es uno de los mejores ejemplos: una enfermedad autosómica dominante causada por una mutación del cromosoma 4p16.3 en el gen IT15. La replicación CAG varía en un rango normal de 10 a 36 replicaciones; sin embargo, en los pacientes con enfermedad de Huntington el rango es de 37 a 121 replicaciones. Esta mutación del triplete CAG en IT15 codifica una poliglutamina denominada "huntingtina". Característicamente mientras más replicaciones de los tripletes son encontradas en un individuo, más precoz es la presentación de los síntomas de la enfermedad (

La replicación de tripletes CAG en diferentes genes causa enfermedades, como la atrofia palidoluysial y las ataxias espinocerebelosas 1, 2, 3, 6 y 7, estas últimas corresponden a un grupo de enfermedades heredodegenerativas en las que el síntoma eje es la ataxia, donde el estudio genético se ha transformado en una poderosa herramienta para el diagnóstico diferencial (

La posibilidad de tener un diagnóstico prenatal y de los estados presintomáticos de estas enfermedades nos plantean problemas éticos sobre cómo actuar o aconsejar (

El desarrollo de nuevas líneas de investigación con modelos animales transgénicos de la enfermedad de Huntington, es decir, animales a los que se les ha transferido el gen patológico a su genoma, han demostrado que la acumulación de la "huntingtina" proteína mutante es fundamental para la expresión de la enfermedad y que, si podemos evitar su agregación, detenemos el proceso de la enfermedad. En otros intentos se ha podido estudiar diferentes estrategias terapéuticas o determinar el rol fisiológico de la "huntingtina" y las secuelas que produce su déficit (

Otras patologías, como la enfermedad de Parkinson, en la que la relación con los factores genéticos es menos clara, representan un mayor desafío. La evidencia acumulada en el sentido que los parientes en primer grado de estos pacientes tienen un riesgo relativo mayor de presentar la enfermedad es 2,3 veces que el de los controles (

La terapia génica ha abierto nuevas perspectivas al tratamiento de muchas enfermedades, la que se basa esencialmente en el desarrollo de sistemas de transferencia de genes que sean seguros, eficaces, capaces de actuar en células que no se dividan como las neuronas y determinar una expresión estable del gen introducido con objetivos terapéuticos. Esto ha resultado un objetivo difícil de alcanzar por una variedad de problemas, determinados tanto por el huésped como por los vectores virales. Los virus que permitirían transferir un gen determinado, en la mayoría de los casos, requieren la transformación del virus, eliminándole las secciones que éste requiere para replicarse o le confieren patogenicidad. En la enfermedad de Parkinson la terapia génica ha sido llamada el "tercer paso". En el primer paso se introdujo la terapia sustitutiva con la levodopa, el segundo fue la sustitución de las neuronas perdidas mediante los implantes de células dopaminérgicas y el tercer paso la entrega de factores tróficos, especialmente el factor neurotrófico glial (GDNF) que rescata las neuronas dopaminérgicas perdidas, revirtiendo el déficit motor en los primates con parkinsonismo inducido por MPTP (

Un esfuerzo importante para colectar la información sobre las enfermedades genéticas se puede encontrar en GeneClinics: Medical Genetics Knowledge Base de la Universidad de Washington (

 

1. Emilien G, Pochon M, Caldas C, Isacson O, Maloteaux. Impact of genomic on drug discovery and clinical medicine. QJM 2000; 93:391-423         [ Links ]2. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72:971-83         [ Links ]3. Albin RL, Tagle DA. Genetics and molecular biology of Huntington's disease. TINS 1995; 18:11-4         [ Links ]4. Reddy PS, Housman DE. The complex pathology of trinucleotide repeats. Curr Opin Cell Biol 1997; 9:364-72         [ Links ]5. Klockgether T. Recent advances in degenerative ataxias. Current Opinion in Neurology 2000; 13:451-5         [ Links ]6. Tyler A, Quarrell OW, Lazarou LP, Meredith AL, Harper PS. Exclusion testing in pregnancy for Huntington's disease. J Med Genet 1990; 27:488-95         [ Links ]7. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's diseaseCell 2000; 101:57-66         [ Links ]8. Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease J Neuroscience 2000; 20:4389-97         [ Links ]9. Dragatsis I, Levine MS, Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice.Nature Genetics 2000; 26:300-6        [ Links ]10. Marder K, Tang MX, Mejia H. Risk of Parkinson´s disease among first degree relative: a community based study. Neurology 1996; 47:155-60         [ Links ]11. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045-7         [ Links ]12. The French Parkinson's Disease Study Group Alpha-Synuclein gene and Parkinson's disease. Science 1998; 279(5354):1116-7         [ Links ]13. Bandmann O, Marsden D, Wood N. Genetic aspects of Parkinson disease. Mov Disorders 1998; 13:203-11         [ Links ]14. Mellick GD, Buchanan DB, McCann SJ, James KM, Johnson AG, Davis DR et al. Le Couteur Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease. Mov Disord 1999; 14:219-24         [ Links ]15. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson's disease, pesticides and glutathione transferase polymorphismsLancet 1998; 352:1344-6         [ Links ]16. Latchman D, Coffin R. Viral Vectors in the treatment of Parkinson Disease. Mov Disorders 2000; 15:9-17         [ Links ]17. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994; 91:5104-8        [ Links ]18. Lars O. Cambating Parkinson´s Disease ­ Step Three. Science 2000; 290:721-4         [ Links ]19. GeneClinics: Medical Genetics Knowledge Base. Copyright, University of Washington, Seattle. 1995-. Updated weekly. Available at 

2. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72:971-83         [ Links ]3. Albin RL, Tagle DA. Genetics and molecular biology of Huntington's disease. TINS 1995; 18:11-4         [ Links ]4. Reddy PS, Housman DE. The complex pathology of trinucleotide repeats. Curr Opin Cell Biol 1997; 9:364-72         [ Links ]5. Klockgether T. Recent advances in degenerative ataxias. Current Opinion in Neurology 2000; 13:451-5         [ Links ]6. Tyler A, Quarrell OW, Lazarou LP, Meredith AL, Harper PS. Exclusion testing in pregnancy for Huntington's disease. J Med Genet 1990; 27:488-95         [ Links ]7. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's diseaseCell 2000; 101:57-66         [ Links ]8. Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease J Neuroscience 2000; 20:4389-97         [ Links ]9. Dragatsis I, Levine MS, Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice.Nature Genetics 2000; 26:300-6        [ Links ]10. Marder K, Tang MX, Mejia H. Risk of Parkinson´s disease among first degree relative: a community based study. Neurology 1996; 47:155-60         [ Links ]11. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045-7         [ Links ]12. The French Parkinson's Disease Study Group Alpha-Synuclein gene and Parkinson's disease. Science 1998; 279(5354):1116-7         [ Links ]13. Bandmann O, Marsden D, Wood N. Genetic aspects of Parkinson disease. Mov Disorders 1998; 13:203-11         [ Links ]14. Mellick GD, Buchanan DB, McCann SJ, James KM, Johnson AG, Davis DR et al. Le Couteur Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease. Mov Disord 1999; 14:219-24         [ Links ]15. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson's disease, pesticides and glutathione transferase polymorphismsLancet 1998; 352:1344-6         [ Links ]16. Latchman D, Coffin R. Viral Vectors in the treatment of Parkinson Disease. Mov Disorders 2000; 15:9-17         [ Links ]17. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994; 91:5104-8        [ Links ]18. Lars O. Cambating Parkinson´s Disease ­ Step Three. Science 2000; 290:721-4         [ Links ]19. GeneClinics: Medical Genetics Knowledge Base. Copyright, University of Washington, Seattle. 1995-. Updated weekly. Available at 

3. Albin RL, Tagle DA. Genetics and molecular biology of Huntington's disease. TINS 1995; 18:11-4         [ Links ]4. Reddy PS, Housman DE. The complex pathology of trinucleotide repeats. Curr Opin Cell Biol 1997; 9:364-72         [ Links ]5. Klockgether T. Recent advances in degenerative ataxias. Current Opinion in Neurology 2000; 13:451-5         [ Links ]6. Tyler A, Quarrell OW, Lazarou LP, Meredith AL, Harper PS. Exclusion testing in pregnancy for Huntington's disease. J Med Genet 1990; 27:488-95         [ Links ]7. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's diseaseCell 2000; 101:57-66         [ Links ]8. Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease J Neuroscience 2000; 20:4389-97         [ Links ]9. Dragatsis I, Levine MS, Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice.Nature Genetics 2000; 26:300-6        [ Links ]10. Marder K, Tang MX, Mejia H. Risk of Parkinson´s disease among first degree relative: a community based study. Neurology 1996; 47:155-60         [ Links ]11. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045-7         [ Links ]12. The French Parkinson's Disease Study Group Alpha-Synuclein gene and Parkinson's disease. Science 1998; 279(5354):1116-7         [ Links ]13. Bandmann O, Marsden D, Wood N. Genetic aspects of Parkinson disease. Mov Disorders 1998; 13:203-11         [ Links ]14. Mellick GD, Buchanan DB, McCann SJ, James KM, Johnson AG, Davis DR et al. Le Couteur Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease. Mov Disord 1999; 14:219-24         [ Links ]15. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson's disease, pesticides and glutathione transferase polymorphismsLancet 1998; 352:1344-6         [ Links ]16. Latchman D, Coffin R. Viral Vectors in the treatment of Parkinson Disease. Mov Disorders 2000; 15:9-17         [ Links ]17. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994; 91:5104-8        [ Links ]18. Lars O. Cambating Parkinson´s Disease ­ Step Three. Science 2000; 290:721-4         [ Links ]19. GeneClinics: Medical Genetics Knowledge Base. Copyright, University of Washington, Seattle. 1995-. Updated weekly. Available at 

4. Reddy PS, Housman DE. The complex pathology of trinucleotide repeats. Curr Opin Cell Biol 1997; 9:364-72         [ Links ]5. Klockgether T. Recent advances in degenerative ataxias. Current Opinion in Neurology 2000; 13:451-5         [ Links ]6. Tyler A, Quarrell OW, Lazarou LP, Meredith AL, Harper PS. Exclusion testing in pregnancy for Huntington's disease. J Med Genet 1990; 27:488-95         [ Links ]7. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's diseaseCell 2000; 101:57-66         [ Links ]8. Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease J Neuroscience 2000; 20:4389-97         [ Links ]9. Dragatsis I, Levine MS, Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice.Nature Genetics 2000; 26:300-6        [ Links ]10. Marder K, Tang MX, Mejia H. Risk of Parkinson´s disease among first degree relative: a community based study. Neurology 1996; 47:155-60         [ Links ]11. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045-7         [ Links ]12. The French Parkinson's Disease Study Group Alpha-Synuclein gene and Parkinson's disease. Science 1998; 279(5354):1116-7         [ Links ]13. Bandmann O, Marsden D, Wood N. Genetic aspects of Parkinson disease. Mov Disorders 1998; 13:203-11         [ Links ]14. Mellick GD, Buchanan DB, McCann SJ, James KM, Johnson AG, Davis DR et al. Le Couteur Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease. Mov Disord 1999; 14:219-24         [ Links ]15. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson's disease, pesticides and glutathione transferase polymorphismsLancet 1998; 352:1344-6         [ Links ]16. Latchman D, Coffin R. Viral Vectors in the treatment of Parkinson Disease. Mov Disorders 2000; 15:9-17         [ Links ]17. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994; 91:5104-8        [ Links ]18. Lars O. Cambating Parkinson´s Disease ­ Step Three. Science 2000; 290:721-4         [ Links ]19. GeneClinics: Medical Genetics Knowledge Base. Copyright, University of Washington, Seattle. 1995-. Updated weekly. Available at 

5. Klockgether T. Recent advances in degenerative ataxias. Current Opinion in Neurology 2000; 13:451-5         [ Links ]6. Tyler A, Quarrell OW, Lazarou LP, Meredith AL, Harper PS. Exclusion testing in pregnancy for Huntington's disease. J Med Genet 1990; 27:488-95         [ Links ]7. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's diseaseCell 2000; 101:57-66         [ Links ]8. Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease J Neuroscience 2000; 20:4389-97         [ Links ]9. Dragatsis I, Levine MS, Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice.Nature Genetics 2000; 26:300-6        [ Links ]10. Marder K, Tang MX, Mejia H. Risk of Parkinson´s disease among first degree relative: a community based study. Neurology 1996; 47:155-60         [ Links ]11. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045-7         [ Links ]12. The French Parkinson's Disease Study Group Alpha-Synuclein gene and Parkinson's disease. Science 1998; 279(5354):1116-7         [ Links ]13. Bandmann O, Marsden D, Wood N. Genetic aspects of Parkinson disease. Mov Disorders 1998; 13:203-11         [ Links ]14. Mellick GD, Buchanan DB, McCann SJ, James KM, Johnson AG, Davis DR et al. Le Couteur Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease. Mov Disord 1999; 14:219-24         [ Links ]15. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson's disease, pesticides and glutathione transferase polymorphismsLancet 1998; 352:1344-6         [ Links ]16. Latchman D, Coffin R. Viral Vectors in the treatment of Parkinson Disease. Mov Disorders 2000; 15:9-17         [ Links ]17. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994; 91:5104-8        [ Links ]18. Lars O. Cambating Parkinson´s Disease ­ Step Three. Science 2000; 290:721-4         [ Links ]19. GeneClinics: Medical Genetics Knowledge Base. Copyright, University of Washington, Seattle. 1995-. Updated weekly. Available at 

6. Tyler A, Quarrell OW, Lazarou LP, Meredith AL, Harper PS. Exclusion testing in pregnancy for Huntington's disease. J Med Genet 1990; 27:488-95         [ Links ]7. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's diseaseCell 2000; 101:57-66         [ Links ]8. Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease J Neuroscience 2000; 20:4389-97         [ Links ]9. Dragatsis I, Levine MS, Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice.Nature Genetics 2000; 26:300-6        [ Links ]10. Marder K, Tang MX, Mejia H. Risk of Parkinson´s disease among first degree relative: a community based study. Neurology 1996; 47:155-60         [ Links ]11. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045-7         [ Links ]12. The French Parkinson's Disease Study Group Alpha-Synuclein gene and Parkinson's disease. Science 1998; 279(5354):1116-7         [ Links ]13. Bandmann O, Marsden D, Wood N. Genetic aspects of Parkinson disease. Mov Disorders 1998; 13:203-11         [ Links ]14. Mellick GD, Buchanan DB, McCann SJ, James KM, Johnson AG, Davis DR et al. Le Couteur Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease. Mov Disord 1999; 14:219-24         [ Links ]15. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson's disease, pesticides and glutathione transferase polymorphismsLancet 1998; 352:1344-6         [ Links ]16. Latchman D, Coffin R. Viral Vectors in the treatment of Parkinson Disease. Mov Disorders 2000; 15:9-17         [ Links ]17. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994; 91:5104-8        [ Links ]18. Lars O. Cambating Parkinson´s Disease ­ Step Three. Science 2000; 290:721-4         [ Links ]19. GeneClinics: Medical Genetics Knowledge Base. Copyright, University of Washington, Seattle. 1995-. Updated weekly. Available at 

7. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's diseaseCell 2000; 101:57-66         [ Links ]8. Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease J Neuroscience 2000; 20:4389-97         [ Links ]9. Dragatsis I, Levine MS, Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice.Nature Genetics 2000; 26:300-6        [ Links ]10. Marder K, Tang MX, Mejia H. Risk of Parkinson´s disease among first degree relative: a community based study. Neurology 1996; 47:155-60         [ Links ]11. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045-7         [ Links ]12. The French Parkinson's Disease Study Group Alpha-Synuclein gene and Parkinson's disease. Science 1998; 279(5354):1116-7         [ Links ]13. Bandmann O, Marsden D, Wood N. Genetic aspects of Parkinson disease. Mov Disorders 1998; 13:203-11         [ Links ]14. Mellick GD, Buchanan DB, McCann SJ, James KM, Johnson AG, Davis DR et al. Le Couteur Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease. Mov Disord 1999; 14:219-24         [ Links ]15. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson's disease, pesticides and glutathione transferase polymorphismsLancet 1998; 352:1344-6         [ Links ]16. Latchman D, Coffin R. Viral Vectors in the treatment of Parkinson Disease. Mov Disorders 2000; 15:9-17         [ Links ]17. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994; 91:5104-8        [ Links ]18. Lars O. Cambating Parkinson´s Disease ­ Step Three. Science 2000; 290:721-4         [ Links ]19. GeneClinics: Medical Genetics Knowledge Base. Copyright, University of Washington, Seattle. 1995-. Updated weekly. Available at 

8. Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease J Neuroscience 2000; 20:4389-97         [ Links ]9. Dragatsis I, Levine MS, Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice.Nature Genetics 2000; 26:300-6        [ Links ]10. Marder K, Tang MX, Mejia H. Risk of Parkinson´s disease among first degree relative: a community based study. Neurology 1996; 47:155-60         [ Links ]11. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045-7         [ Links ]12. The French Parkinson's Disease Study Group Alpha-Synuclein gene and Parkinson's disease. Science 1998; 279(5354):1116-7         [ Links ]13. Bandmann O, Marsden D, Wood N. Genetic aspects of Parkinson disease. Mov Disorders 1998; 13:203-11         [ Links ]14. Mellick GD, Buchanan DB, McCann SJ, James KM, Johnson AG, Davis DR et al. Le Couteur Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease. Mov Disord 1999; 14:219-24         [ Links ]15. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson's disease, pesticides and glutathione transferase polymorphismsLancet 1998; 352:1344-6         [ Links ]16. Latchman D, Coffin R. Viral Vectors in the treatment of Parkinson Disease. Mov Disorders 2000; 15:9-17         [ Links ]17. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994; 91:5104-8        [ Links ]18. Lars O. Cambating Parkinson´s Disease ­ Step Three. Science 2000; 290:721-4         [ Links ]19. GeneClinics: Medical Genetics Knowledge Base. Copyright, University of Washington, Seattle. 1995-. Updated weekly. Available at 

9. Dragatsis I, Levine MS, Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice.Nature Genetics 2000; 26:300-6        [ Links ]10. Marder K, Tang MX, Mejia H. Risk of Parkinson´s disease among first degree relative: a community based study. Neurology 1996; 47:155-60         [ Links ]11. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045-7         [ Links ]12. The French Parkinson's Disease Study Group Alpha-Synuclein gene and Parkinson's disease. Science 1998; 279(5354):1116-7         [ Links ]13. Bandmann O, Marsden D, Wood N. Genetic aspects of Parkinson disease. Mov Disorders 1998; 13:203-11         [ Links ]14. Mellick GD, Buchanan DB, McCann SJ, James KM, Johnson AG, Davis DR et al. Le Couteur Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease. Mov Disord 1999; 14:219-24         [ Links ]15. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson's disease, pesticides and glutathione transferase polymorphismsLancet 1998; 352:1344-6         [ Links ]16. Latchman D, Coffin R. Viral Vectors in the treatment of Parkinson Disease. Mov Disorders 2000; 15:9-17         [ Links ]17. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994; 91:5104-8        [ Links ]18. Lars O. Cambating Parkinson´s Disease ­ Step Three. Science 2000; 290:721-4         [ Links ]19. GeneClinics: Medical Genetics Knowledge Base. Copyright, University of Washington, Seattle. 1995-. Updated weekly. Available at 

10. Marder K, Tang MX, Mejia H. Risk of Parkinson´s disease among first degree relative: a community based study. Neurology 1996; 47:155-60         [ Links ]11. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045-7         [ Links ]12. The French Parkinson's Disease Study Group Alpha-Synuclein gene and Parkinson's disease. Science 1998; 279(5354):1116-7         [ Links ]13. Bandmann O, Marsden D, Wood N. Genetic aspects of Parkinson disease. Mov Disorders 1998; 13:203-11         [ Links ]14. Mellick GD, Buchanan DB, McCann SJ, James KM, Johnson AG, Davis DR et al. Le Couteur Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease. Mov Disord 1999; 14:219-24         [ Links ]15. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson's disease, pesticides and glutathione transferase polymorphismsLancet 1998; 352:1344-6         [ Links ]16. Latchman D, Coffin R. Viral Vectors in the treatment of Parkinson Disease. Mov Disorders 2000; 15:9-17         [ Links ]17. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994; 91:5104-8        [ Links ]18. Lars O. Cambating Parkinson´s Disease ­ Step Three. Science 2000; 290:721-4         [ Links ]19. GeneClinics: Medical Genetics Knowledge Base. Copyright, University of Washington, Seattle. 1995-. Updated weekly. Available at 

11. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045-7         [ Links ]12. The French Parkinson's Disease Study Group Alpha-Synuclein gene and Parkinson's disease. Science 1998; 279(5354):1116-7         [ Links ]13. Bandmann O, Marsden D, Wood N. Genetic aspects of Parkinson disease. Mov Disorders 1998; 13:203-11         [ Links ]14. Mellick GD, Buchanan DB, McCann SJ, James KM, Johnson AG, Davis DR et al. Le Couteur Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease. Mov Disord 1999; 14:219-24         [ Links ]15. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson's disease, pesticides and glutathione transferase polymorphismsLancet 1998; 352:1344-6         [ Links ]16. Latchman D, Coffin R. Viral Vectors in the treatment of Parkinson Disease. Mov Disorders 2000; 15:9-17         [ Links ]17. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994; 91:5104-8        [ Links ]18. Lars O. Cambating Parkinson´s Disease ­ Step Three. Science 2000; 290:721-4         [ Links ]19. GeneClinics: Medical Genetics Knowledge Base. Copyright, University of Washington, Seattle. 1995-. Updated weekly. Available at 

12. The French Parkinson's Disease Study Group Alpha-Synuclein gene and Parkinson's disease. Science 1998; 279(5354):1116-7         [ Links ]13. Bandmann O, Marsden D, Wood N. Genetic aspects of Parkinson disease. Mov Disorders 1998; 13:203-11         [ Links ]14. Mellick GD, Buchanan DB, McCann SJ, James KM, Johnson AG, Davis DR et al. Le Couteur Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease. Mov Disord 1999; 14:219-24         [ Links ]15. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson's disease, pesticides and glutathione transferase polymorphismsLancet 1998; 352:1344-6         [ Links ]16. Latchman D, Coffin R. Viral Vectors in the treatment of Parkinson Disease. Mov Disorders 2000; 15:9-17         [ Links ]17. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994; 91:5104-8        [ Links ]18. Lars O. Cambating Parkinson´s Disease ­ Step Three. Science 2000; 290:721-4         [ Links ]19. GeneClinics: Medical Genetics Knowledge Base. Copyright, University of Washington, Seattle. 1995-. Updated weekly. Available at 

13. Bandmann O, Marsden D, Wood N. Genetic aspects of Parkinson disease. Mov Disorders 1998; 13:203-11         [ Links ]14. Mellick GD, Buchanan DB, McCann SJ, James KM, Johnson AG, Davis DR et al. Le Couteur Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease. Mov Disord 1999; 14:219-24         [ Links ]15. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson's disease, pesticides and glutathione transferase polymorphismsLancet 1998; 352:1344-6         [ Links ]16. Latchman D, Coffin R. Viral Vectors in the treatment of Parkinson Disease. Mov Disorders 2000; 15:9-17         [ Links ]17. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994; 91:5104-8        [ Links ]18. Lars O. Cambating Parkinson´s Disease ­ Step Three. Science 2000; 290:721-4         [ Links ]19. GeneClinics: Medical Genetics Knowledge Base. Copyright, University of Washington, Seattle. 1995-. Updated weekly. Available at 

14. Mellick GD, Buchanan DB, McCann SJ, James KM, Johnson AG, Davis DR et al. Le Couteur Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease. Mov Disord 1999; 14:219-24         [ Links ]15. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson's disease, pesticides and glutathione transferase polymorphismsLancet 1998; 352:1344-6         [ Links ]16. Latchman D, Coffin R. Viral Vectors in the treatment of Parkinson Disease. Mov Disorders 2000; 15:9-17         [ Links ]17. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994; 91:5104-8        [ Links ]18. Lars O. Cambating Parkinson´s Disease ­ Step Three. Science 2000; 290:721-4         [ Links ]19. GeneClinics: Medical Genetics Knowledge Base. Copyright, University of Washington, Seattle. 1995-. Updated weekly. Available at 

15. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson's disease, pesticides and glutathione transferase polymorphismsLancet 1998; 352:1344-6         [ Links ]16. Latchman D, Coffin R. Viral Vectors in the treatment of Parkinson Disease. Mov Disorders 2000; 15:9-17         [ Links ]17. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994; 91:5104-8        [ Links ]18. Lars O. Cambating Parkinson´s Disease ­ Step Three. Science 2000; 290:721-4         [ Links ]19. GeneClinics: Medical Genetics Knowledge Base. Copyright, University of Washington, Seattle. 1995-. Updated weekly. Available at 

16. Latchman D, Coffin R. Viral Vectors in the treatment of Parkinson Disease. Mov Disorders 2000; 15:9-17         [ Links ]17. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994; 91:5104-8        [ Links ]18. Lars O. Cambating Parkinson´s Disease ­ Step Three. Science 2000; 290:721-4         [ Links ]19. GeneClinics: Medical Genetics Knowledge Base. Copyright, University of Washington, Seattle. 1995-. Updated weekly. Available at 

17. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994; 91:5104-8        [ Links ]18. Lars O. Cambating Parkinson´s Disease ­ Step Three. Science 2000; 290:721-4         [ Links ]19. GeneClinics: Medical Genetics Knowledge Base. Copyright, University of Washington, Seattle. 1995-. Updated weekly. Available at 

18. Lars O. Cambating Parkinson´s Disease ­ Step Three. Science 2000; 290:721-4         [ Links ]19. GeneClinics: Medical Genetics Knowledge Base. Copyright, University of Washington, Seattle. 1995-. Updated weekly. Available at 

19. GeneClinics: Medical Genetics Knowledge Base. Copyright, University of Washington, Seattle. 1995-. Updated weekly. Available at 

20. Online Mendelian Inheritance in Man, OMIM (TM). McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD), 2000. World Wide Web URL: 

 